LEADER 02300nam 2200361 450 001 9910597903603321 005 20230219120625.0 035 $a(CKB)4100000003666497 035 $a(NjHacI)994100000003666497 035 $a(EXLCZ)994100000003666497 100 $a20230219d2018 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aToxins in Drug Discovery and Pharmacology /$fedited by Steve Peigneur 210 1$aBasel, Switzerland :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2018. 215 $a1 online resource (316 pages) 311 $a3-03842-861-2 330 $aVenoms from marine and terrestrial animals (cone snails, scorpions, spiders, snakes, centipedes, cnidarian, etc.) can be seen as an untapped cocktail of biologically-active compounds, being increasingly recognized as new emerging source of peptide-based therapeutics. Venomous animals are considered to be specialized predators that have evolved the most sophisticated peptide chemistry and neuropharmacology for their own biological purposes by producing venoms that contains a structural and functional diversity of neurotoxins. These neurotoxins have shown to be highly selective ligands for a wide range of ion channels and receptors. Therefore, they represent interesting lead compounds for the development of, for example, analgesics, anti-cancer drugs, drugs for neurological disorders such as multiple sclerosis, Parkinson's disease, Alzheimer's disease, etc. This Special Issue of Toxins aims to provide a comprehensive look at toxins and toxin inspired leads and will focus on the mechanism of action, structure-function and evolution of pharmacological interesting venom components, including but not limited to, recent developments relating to the emergence of venoms as an underutilized source of highly evolved bioactive peptides with clinical potential. 606 $aPharmacology 606 $aToxins 615 0$aPharmacology. 615 0$aToxins. 676 $a615.373 702 $aPeigneur$b Steve 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910597903603321 996 $aToxins in Drug Discovery and Pharmacology$92929121 997 $aUNINA